SKAN Group AG
SIX:SKAN

Watchlist Manager
SKAN Group AG Logo
SKAN Group AG
SIX:SKAN
Watchlist
Price: 47.4 CHF -0.73% Market Closed
Market Cap: CHf1.1B

EV/EBIT

43.3
Current
6%
Cheaper
vs 3-y average of 46.1

Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBIT
43.3
=
Enterprise Value
CHf986.6m
/
EBIT
CHf25.4m

Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBIT
43.3
=
Enterprise Value
CHf986.6m
/
EBIT
CHf25.4m

Valuation Scenarios

SKAN Group AG is trading below its 3-year average

If EV/EBIT returns to its 3-Year Average (46.1), the stock would be worth CHf50.41 (6% upside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-55%
Maximum Upside
+10%
Average Downside
17%
Scenario EV/EBIT Value Implied Price Upside/Downside
Current Multiple 43.3 CHf47.4
0%
3-Year Average 46.1 CHf50.41
+6%
5-Year Average 47.5 CHf51.96
+10%
Industry Average 30 CHf32.81
-31%
Country Average 19.5 CHf21.37
-55%

Forward EV/EBIT
Today’s price vs future ebit

Today's Enterprise Value EBIT Forward EV/EBIT
CHf986.6m
/
Jan 2026
CHf25.4m
=
43.3
Current
CHf986.6m
/
Dec 2026
CHf49.7m
=
19.9
Forward
CHf986.6m
/
Dec 2027
CHf62m
=
15.9
Forward
CHf986.6m
/
Dec 2028
CHf98.7m
=
10
Forward

Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.

Peer Comparison

All Multiples
EV/EBIT
P/E
All Countries
Close
Market Cap EV/EBIT P/E
CH
SKAN Group AG
SIX:SKAN
1.1B CHF 43.3 66.6
US
PerkinElmer Inc
LSE:0KHE
1T USD 2 361.7 4 280.5
US
Thermo Fisher Scientific Inc
NYSE:TMO
193.4B USD 24.4 25.9
US
Danaher Corp
NYSE:DHR
130.1B USD 26.1 35
KR
Samsung Biologics Co Ltd
KRX:207940
82.3T KRW 39.4 46.1
CH
Lonza Group AG
SIX:LONN
34.9B CHF 26.2 -122.3
CN
WuXi AppTec Co Ltd
SSE:603259
296.1B CNY 16.2 15.6
US
Agilent Technologies Inc
NYSE:A
34.1B USD 21.7 24.9
US
Waters Corp
NYSE:WAT
32.8B USD 38.5 47.4
US
IQVIA Holdings Inc
NYSE:IQV
29.7B USD 17 20
US
Mettler-Toledo International Inc
NYSE:MTD
26.7B USD 24.1 29.3

Market Distribution

Higher than 90% of companies in Switzerland
Percentile
90th
Based on 894 companies
90th percentile
43.3
Low
0 — 13.5
Typical Range
13.5 — 25.3
High
25.3 —
Distribution Statistics
Switzerland
Min 0
30th Percentile 13.5
Median 19.5
70th Percentile 25.3
Max 855.5

SKAN Group AG
Glance View

SKAN Group AG, headquartered in Switzerland, has carved out its niche as a leading innovator in the realm of contamination control for aseptic environments. The company's history traces back to its founding in 1968, following the rapid advancements in the pharmaceutical and biotechnology sectors. SKAN has since developed a sterling reputation for its pioneering work in isolator technology, offering solutions that ensure the highest standards of sterility and safety critical to these industries. The company designs and manufactures isolators, which are essentially sealed environments that provide contamination-free zones for the processing of materials or production of pharmaceuticals, ensuring that even the most sensitive products are handled with stringent safety measures. This focus on high-tech, specialized equipment forms the backbone of SKAN's revenue model. By providing bespoke solutions tailored to the unique requirements of its clients, SKAN taps into the lucrative markets of pharmaceutical production and research, biotechnology companies, and laboratories that demand high-performance contamination barriers. Beyond just the sale of equipment, SKAN also offers a comprehensive suite of services, including installation, validation, maintenance, and training, ensuring a steady flow of income as these businesses need continual updates and technical support for their critical infrastructure. The demand for stricter health regulations and more advanced pharmaceuticals continues to rise, positioning SKAN Group AG as a pivotal player in this essential industry, capitalizing on its expertise to ensure both safety and compliance for its customers worldwide.

SKAN Intrinsic Value
68.31 CHF
Undervaluation 31%
Intrinsic Value
Price CHf47.4
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett